Latest news

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

Debiopharm Extends SunRock Biopharma Partnership for Antibody-Drug Conjugates Targeting HER3 in EGFR Mutated Cancers

Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-Treat Cancers

Big Impact, Small Package: Debiopharm Launches a Wazoku Open-Innovation Challenge for Small Antibody Drug Conjugate Technology

Debiopharm and Ubix Therapeutics launch research to develop a new anti-cancer modality – antibody degraducer® conjugates

Debiopharm and Genome & Company Join Forces to Create New Highly Specific Therapies For Cancer Patients